



## Hepatitis and Vaccines

Guest Editor:

### **Dr. Jessica Howell**

1. Department of Gastroenterology, St Vincent's Hospital Melbourne, Fitzroy, VIC 3065, Australia
2. Department of Medicine, University of Melbourne, Parkville, VIC 3010, Australia
3. Disease Elimination Program, Burnet Institute, Melbourne VIC, 3004, Australia
4. Department of Epidemiology and Preventive Medicine, Monash University, Clayton, VIC 3800, Australia

Deadline for manuscript submissions:

**closed (31 October 2022)**

### **Message from the Guest Editor**

Dear Colleagues,

The WHO has set elimination targets to achieve by 2030 to reduce the global burden of morbidity and mortality due to viral hepatitis. Prevention strategies, including vaccination, remain the cornerstone of this goal. There is a highly effective vaccine against the hepatitis B virus; however, timely delivery of the birth dose remains a major challenge worldwide. To overcome this hurdle, novel delivery devices and protocols such as delivery outside of the “cold chain” have been explored but not widely implemented. Currently, there is no effective vaccine available for hepatitis C, yet important work continues in this field. Advances in vaccine technology made through the development of vaccines against SARS-CoV-2 will further catalyze novel approaches to viral hepatitis vaccination development.

This Special Edition of Vaccines will cover topics relevant to vaccination in viral hepatitis, including novel vaccine delivery strategies, hepatitis C vaccine development, the role of therapeutic vaccines, and the modeled impact and cost-effectiveness of vaccination strategies to achieve viral hepatitis elimination.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)